Active Comparator (erlotinib) — Competitive Intelligence Brief

Active Comparator (erlotinib) (Active Comparator (erlotinib)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor. Area: Oncology.

phase 3 EGFR tyrosine kinase inhibitor EGFR (epidermal growth factor receptor) Oncology Small molecule

Target snapshot

Active Comparator (erlotinib) (Active Comparator (erlotinib)) — Pfizer. Erlotinib is a tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active Comparator (erlotinib) TARGET	Active Comparator (erlotinib)	Pfizer	phase 3	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
Sequential Icotinib Plus Chemotherapy	Sequential Icotinib Plus Chemotherapy	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
placebo matching lapatinib	placebo matching lapatinib	GlaxoSmithKline	marketed	HER2/EGFR tyrosine kinase inhibitor	HER2, EGFR
Maintenance icotinib	Maintenance icotinib	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor (TKI)	EGFR (epidermal growth factor receptor)
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Sequential and maintenance icotinib	Sequential and maintenance icotinib	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor class)

1. Betta Pharmaceuticals Co., Ltd. · 4 drugs in this class
2. Hangzhou ACEA Pharmaceutical Research Co., Ltd. · 2 drugs in this class
3. Genentech, Inc. · 2 drugs in this class
4. AstraZeneca · 2 drugs in this class
5. Millennium Pharmaceuticals, Inc. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Sichuan Cancer Hospital and Research Institute · 1 drug in this class
8. Sun Yat-sen University · 1 drug in this class
9. University of Chicago · 1 drug in this class
10. Xinqiao Hospital of Chongqing · 1 drug in this class